Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use. - Card KG; Grewal A; Closson K; Martin G; Baracaldo L; Allison S; Kruger DJ; Walsh Z (Journal of psychoactive drugs, 2024)

Mystical and Affective Aspects of Psychedelic Use in a Naturalistic Setting: A Linguistic Analysis of Online Experience Reports. - Žuljević MF; Mijatović A; Marušić SL; Kudrjavets G; Buljan I; Hren D (Journal of psychoactive drugs, 2024)

Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens. - Rahman SM; Salem Y; Hussain A (Dermatitis: contact, atopic, occupational, drug, 2024)

Evaluation of TrpM and PsiD substrate promiscuity reveals new biocatalytic capabilities. - Kanis FC; Broude CN; Hellwarth EB; Gibbons WJ; Sen AK; Adams AM; Wang X; Jones JA (Biotechnology progress, 2024)

Fire Kasina advanced meditation produces experiences comparable to psychedelic and near-death experiences: A pilot study. - Woollacott M; Riddle J; Hermansson N; Sacchet MD; Ingram DM (Explore (New York, N.Y.), 2024)

Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study. - Rucker J; Butler M; Hambleton S; Bird C; Seynaeve M; Cheema S; Campbell-Coker K; Maggio C; Dunbar F; Lambru G; Matharu M (Headache, 2024)

Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial. - Lee J; Philip K; Wijeysundera DN; Clarke H; Pritlove C; Katz J; Ritvo P; Goel A; Husain MI; Ladha KS (Canadian journal of pain = Revue canadienne de la douleur, 2024)

A novel method for quantitative analysis of subjective experience reports: application to psychedelic visual experiences. - Noah S; Shen M; Erowid E; Erowid F; Silver M (Frontiers in psychology, 2024)

Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use. - Brett J; Knock E; Watson K; Albert S; Siefried KJ; Guss J (Frontiers in psychiatry, 2024)

Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol. - Butler M; Bird C; Maggio C; Durden A; Modlin N; Campbell-Coker K; Edwards M; Pick S; Millman LSM; Lowery E; Bhagavan C; Kanaan R; et al. (Wellcome open research, 2024)

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans. - Madrid-Gambin F; Fabregat-Safont D; Gomez-Gomez A; Olesti E; Mason NL; Ramaekers JG; Pozo OJ (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023)

Psilocybin Therapy for Depression: A Review of Current Molecular Knowledge - Verheijen Marcha C.T. (Journal of the Netherlands Society of Toxicology, 2023)

Psilocybin - new remedy for patients with psychiatric disorders? Critical analysis of the current state of knowledge - Karolina Wąsik; Sebastian Tomaszuk; Magda Wojtuś (Journal of Education Health and Sport, 2023)

The Therapeutic Effect and Potential Application of Psilocybin - Tianran Liu (Highlights in Science Engineering and Technology, 2023)

Public Interest in Psilocybin and Psychedelic Therapy in the Context of the COVID-19 Pandemic: Google Trends Analysis. - Danias G; Appel J (JMIR formative research, 2023)

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, proof-of-principle, placebo-controlled and crossover, neuroimaging trial in depression - Poulin JM; Bigford GE; Lanctot KL; Giacobbe P; Schaffer A; Sinyor M; Rabin JS; Masellis M; Singnurkar A; Pople CB; Lipsman N; MacIntosh BJ; et al. (Research Square, 2023)

Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview - Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS. (PsyArXiv, 2023)

Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin - Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS. (PsyArXiv, 2023)

Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma. - Multidisciplinary Association for Psychedelic Studies (ClinicalTrials.gov, 2023)

Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview - Burton J. Tabaac; Kenneth Shinozuka; Alejandro Arenas; Bryce D. Beutler; Kirsten Cherian; Viviana D. Evans; Chelsey Fasano; Owen S. Muir (PsyArXiv, 2023)

Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin - Burton J. Tabaac; Kenneth Shinozuka; Alejandro Arenas; Bryce D. Beutler; Kirsten Cherian; Viviana D. Evans; Chelsey Fasano; Owen S. Muir (PsyArXiv, 2023)

Molecular and Medical Aspects of Psychedelics. - Wojtas A; Gołembiowska K (International journal of molecular sciences, 2023)

Application of psilocybin in mental health disorders - Jingxuan Chen (Theoretical and Natural Science, 2023)

Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity. - Du Y; Li Y; Zhao X; Yao Y; Wang B; Zhang L; Wang G (Chinese medical journal, 2023)

Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain. - Kolbman N; Liu T; Guzzo P; Gilligan J; Mashour GA; Vanini G; Pal D (Current biology: CB, 2023)

Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders - Yale University (ClinicalTrials.gov, 2023)

Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue. - Robinson GI; Li D; Wang B; Rahman T; Gerasymchuk M; Hudson D; Kovalchuk O; Kovalchuk I (Life (Basel, Switzerland), 2023)

Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats. - Reinwald JR; Schmitz CN; Skorodumov I; Kuchar M; Weber-Fahr W; Spanagel R; Meinhardt MW (Translational psychiatry, 2023)

Psychedelics and cognitive function: A systematic review - Caíque Gois Cardoso; Milena de Barros Viana (Research Society and Development, 2023)

Psilocybin prevents activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms - Conn K; Milton L; Huang K; Munguba H; Ruuska J; Lemus M; Greaves E; Homman-Ludiye J; Oldfield B; Foldi C. (bioRxiv, 2023)

Development and validation of a sensitive LC-MS-MS method to quantify psilocin in authentic oral fluid samples - Cardoso Marilia Santoro; da Cunha Kelly Francisco; Silva Izabelly Geraldes; Fiorentin Taís Regina; de Campos Eduardo G; Costa Jose Luiz (Journal of Analytical Toxicology, 2023)

Psychotropics: A scientific, regulatory, and public view on the medicinal uses of cannabinoids and psilocybin - Ivana Turek (Medical Writing, 2023)

CHIẾT XUẤT PSILOCIN TỪ NẤM THỨC THẦN LÀM NGUYÊN LIỆU THIẾT LẬP CHUẨN - Trần Nguyên Hà; Đặng Đức Khanh; Phạm Đức Trọng; Nguyễn Xuân Trường (Tạp chí Y học Quân sự, 2023)

Statistical diversity distinguishes global states of consciousness - Starkey J; Carhart-Harris RL; Pigorini A; Nobili L; Barrett AB. (bioRxiv, 2023)

Domestication through clandestine cultivation constrained genetic diversity in magic mushrooms relative to naturalized populations. - McTaggart AR; McLaughlin S; Slot JC; McKernan K; Appleyard C; Bartlett TL; Weinert M; Barlow C; Warne LN; Shuey LS; Drenth A; James TY (Current biology: CB, 2023)

Peer support and psychedelics. - Skiles Z; Dixon JR; Friedrich D; Reed D; Stauffer CS (Journal of military, veteran and family health, 2023)

A history and future of psychedelics: The case of the Canadian military. - Dyck E; Marchildon GP (Journal of military, veteran and family health, 2023)

Studying classic psychedelics for the management of headache disorders: Considerations for Veterans. - Schindler EAD; Sico JJ (Journal of military, veteran and family health, 2023)

Flies on ’Shrooms: Studying the Psychotherapeutic Potential of Psilocybin using Drosophila - Nicoletta Faraone (American Entomologist, 2023)

Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model. - McCrone P; Fisher H; Knight C; Harding R; Schlag AK; Nutt DJ; Neill JC (Psychological medicine, 2023)

Hallucinogen use among young adults ages 19-30 in the United States: Changes from 2018 to 2021. - Keyes KM; Patrick ME (Addiction (Abingdon, England), 2023)

Psilocybin-assisted psychotherapy for treatment-resistant depression: Which psychotherapy? - Crowe M; Manuel J; Carlyle D; Lacey C (International journal of mental health nursing, 2023)

Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study. - Gramling R; Bennett E; Curtis K; Richards W; Rizzo DM; Arnoldy F; Hegg L; Porter J; Honstein H; Pratt S; Tarbi E; Reblin M; et al. (Journal of palliative medicine, 2023)

Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use. - Jones G; Herrmann F; Wang E (Addictive behaviors reports, 2023)

A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond. - Pepe M; Hesami M; de la Cerda KA; Perreault ML; Hsiang T; Jones AMP (Biotechnology advances, 2023)

Potential use of psilocybin drugs in the treatment of depression. - Śladowska K; Kawalec P; Brzostek T; Pilc A (Expert opinion on emerging drugs, 2023)

Cardiovascular safety of psychedelic medicine: current status and future directions. - Wsół A (Pharmacological reports: PR, 2023)

Preclinical models of treatment-resistant depression: challenges and perspectives. - Kolasa M; Faron-Górecka A (Pharmacological reports: PR, 2023)

Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. - Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST (Drug discovery today, 2023)

Mindfulness meditation and psychedelics: potential synergies and commonalities. - Holas P; Kamińska J (Pharmacological reports: PR, 2023)

Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies. - Chruścicka-Smaga B; Machaczka A; Szewczyk B; Pilc A (Pharmacological reports: PR, 2023)

The possible place for psychedelics in pharmacotherapy of mental disorders. - Wojtas A (Pharmacological reports: PR, 2023)

Psilocybin therapy to reduce depression following a terminal diagnosis. - Boudreau E; Orlowski K (JAAPA: official journal of the American Academy of Physician Assistants, 2023)

Psilocybin's Erasure of EGO. - Ahlskog G (Psychoanalytic review, 2023)

Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers. - Mathai DS; Hilbert S; Sepeda ND; Strickland JC; Griffiths RR; Garcia-Romeu A (Psychedelic medicine (New Rochelle, N.Y.), 2023)

Perceptions of psychedelic-assisted therapy among Black Americans. - Carter S; Packard G; Coghlan C; George JR; Brown AJ; Ching THW; Julian J; Maples-Keller JL (Journal of mood and anxiety disorders, 2023)

Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development. - Weintraub MJ; Jeffrey JK; Grob CS; Ichinose MC; Bergman RL; Cooper ZD; Miklowitz DJ (Psychedelic medicine (New Rochelle, N.Y.), 2023)

A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions. - Brennan W; Kelman AR; Belser AB (Psychedelic medicine (New Rochelle, N.Y.), 2023)

Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings. - Nicholas CR; Horton DM; Malicki J; Baltes A; Hutson PR; Brown RT (Psychedelic medicine (New Rochelle, N.Y.), 2023)

The potential of psilocybin use to enhance well-being in healthy individuals - A scoping review - Lennart Wiepking; Eduard J. de Bruin; Alexandra Ghiţă (Journal of Psychedelic Studies, 2023)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD). - Apex Labs Ltd. (ClinicalTrials.gov, 2023)

[Feeling unwell after eating a piece of chocolate]. - van der Schuur-Saleem R; Visser E; Robben H; Zwols M; den Besten-Berthololee D (Nederlands tijdschrift voor geneeskunde, 2023)

Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach - McAlpine R; Krajnović K; Khan M; Morometescu L; Simonsson O; Sacchet M; Kamboj S. (PsyArXiv, 2023)

Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach - Rosalind McAlpine; Katarina Krajnović; Maisha Khan; Larisa Morometescu; Otto Simonsson; Matthew Sacchet; Sunjeev Kamboj (PsyArXiv, 2023)

Altered stakes: Identifying gaps in the informed consent process for psychedelic-assisted therapy trials - Tahlia R. Harrison (Journal of Psychedelic Studies, 2023)

Wood-loving magic mushrooms from Australia are saprotrophic invaders in the northern hemisphere - McTaggart A; Scarlett K; Slot J; Barlow C; Appleyard C; Gardiner D; Fechner N; Tilden J; Hass D; Voogelbreinder S; Lording W; Lloyd R; et al. (Authorea Preprints, 2023)

Psychedelic Integration: Psychotherapy for non-ordinary states of consciousness - Danelle Jones (Journal of Psychedelic Studies, 2023)

The potential use of psilocybin in psychiatry - Kamilė Žalkauskaitė; Justina Kirdeikytė; Vilius Ogenskas (Lithuanian University of Health Sciences, 2023)

Aesthetic Chills Mitigate Maladaptive Cognition In Depression - Schoeller F; Jain A; Adrien V; Maes P; Reggente N. (Research Square, 2023)

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression - COMPASS Pathways (ClinicalTrials.gov, 2023)

The entropic heart: Tracking the psychedelic state via heart rate dynamics - Rosas FE; Mediano PA; Timmermann C; Luppi AI; Candia-Rivera D; Abbasi-Asl R; Gazzaley A; Kringelbach ML; Muthukumaraswamy S; Bor D; Garfinkel S; Carhart-Harris RL. (bioRxiv, 2023)

Managing expectations with psychedelic microdosing - Omer A. Syed; Benjamin Tsang (npj Mental Health Research, 2023)

Pharmacists’ perspectives on psilocybin in Canada - Elizabeth Sugiarto; Rebecca Leung; Jamie Yuen (JAPhA Practice Innovations, 2023)

Beyond the 5-HT Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action. - Cameron LP; Benetatos J; Lewis V; Bonniwell EM; Jaster AM; Moliner R; Castrén E; McCorvy JD; Palner M; Aguilar-Valles A (The Journal of neuroscience: the official journal of the Society for Neuroscience, 2023)

Investigation of the structure, stability, and relative solubility of psilocybin in water and pure organic solvents: A molecular simulation study - Lucas A. Paul; Cyril T. Namba-Nzanguim; Aidani Telesphory; Jehoshaphat Oppong Mensah; Denis Mteremko; Rene Costa; Saidi Mohamedi Katundu; Lucas P. Kwiyukwa; Naserian Daniel Kambaine; Julius Juvenary; Sixberth Mlowe; Geradius Deogratias; et al. (Journal of Molecular Liquids, 2023)

The Potential Therapeutic Benefits and Safety of Psychedelics in the Treatment of Mental Health Conditions: A Systematic Review - 7450 Summit Cir; Davison; MI48423; Sarah Naher (Journal of Sociology Psychology & Religious Studies, 2023)

LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain. - Van Der Walt J; Parker R (South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2023)

Beliefs and Perceived Barriers Regarding Psychedelic-assisted Therapy in a Pilot Study of Service Members and Veterans With a History of Traumatic Brain Injury. - Gray JC; Murphy M; Carter SE; Johnson MW; Wolfgang AS; Roy MJ; Maples-Keller JL (Military medicine, 2023)

A "Magic Mushroom" Multi-Product Sesquiterpene Synthase. - Schäfer E; Seibold PS; Bartram S; Trottmann F; Haensch VG; Gressler M; Chadeayne AR; Hertweck C; O'Connor SE; Hoffmeister D (Chembiochem: a European journal of chemical biology, 2023)

Cultivation, chemistry, and genome of. - Miller DR; Jacobs JT; Rockefeller A; Singer H; Bollinger IM; Conway J; Slot JC; Cliffel DE (bioRxiv: the preprint server for biology, 2023)

Anxiolytic behavior accompanied by the alteration of the intestinal bacteriome during psilocybin treatment - Emese Prandovszky; Zachary A. Cordner; Hua Liu; Megan Pedicini; Lindsey Macias; Kellie L. Tamashiro; Robert H. Yolken (Brain Behavior and Immunity, 2023)

Peak Experiences: Lessons Learned from a Feasibility Study of Psilocybin-assisted Therapy for Demoralization in Patients Receiving Hospice Care - Roxanne Sholevar (Journal of the Academy of Consultation-Liaison Psychiatry, 2023)

Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception - Muller S; Cavanna F; de la Fuente L; Bruno N; D’Amelio TA; Pallavicini C; Tagliazucchi E. (bioRxiv, 2023)

An Integrative Review of Measures of Spirituality in Experimental Studies of Psilocybin in Serious Illness Populations. - Baker KM; Ulrich CM; Meghani SH (The American journal of hospice & palliative care, 2023)

"But the reality is it's happening": A qualitative study of eating disorder providers about psilocybin-assisted psychotherapy. - Downey AE; Boyd M; Chaphekar AV; Woolley J; Raymond-Flesch M (The International journal of eating disorders, 2023)

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. - Perez N; Langlest F; Mallet L; De Pieri M; Sentissi O; Thorens G; Seragnoli F; Zullino D; Kirschner M; Kaiser S; Solmi M; Sabé M (European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2023)

Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study. - Mason NL; Szabo A; Kuypers KPC; Mallaroni PA; de la Torre Fornell R; Reckweg JT; Tse DHY; Hutten NRPW; Feilding A; Ramaekers JG (Brain, behavior, and immunity, 2023)

Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results. - Linguiti S; Vogel JW; Sydnor VJ; Pines A; Wellman N; Basbaum A; Eickhoff CR; Eickhoff SB; Edwards RR; Larsen B; McKinstry-Wu A; Scott JC; et al. (Neuroscience and biobehavioral reviews, 2023)

Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats. - Malikowska-Racia N; Koniewski M; Golebiowska J; Popik P (Journal of psychopharmacology (Oxford, England), 2023)

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. - Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD (Psychiatry research, 2023)

[Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland]. - Olafsson RP; Kvaran K; Ketilsdottir K; Hallgrimsdottir K; Sigurdsson EL; Sigurdsson E (Laeknabladid, 2023)

[Determination of amanita peptide and tryptamine toxins in wild mushrooms by high performance liquid chromatography-tandem mass spectrometry]. - Liu LQ; Chen JZ; Fu WS; Tang CY (Se pu = Chinese journal of chromatography, 2023)

Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential. - Raj P; Rauniyar S; Sapkale B (Cureus, 2023)

The Psychedelic Social Club: a regulatory concept for people who use psychedelics? - Henry Harder; Fabian P. Steinmetz; Maja Kohek (Drugs Education Prevention and Policy, 2023)

A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics. - Banushi B; Polito V (Biology, 2023)

Songs of Life: Psychedelic-Assisted Psychotherapy and Deleuze and Guattari’s ‘Desiring-Production’ - Patricia Kubala (Deleuze and Guattari Studies, 2023)

A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues - Kratina S; Lo C; Schwartz R; Strike C; Jopling S; Nayfeh A; Rush B. (PsyArXiv, 2023)

A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues - Sarah Kratina; Chris Lo; Robert Schwartz; Carol Strike; Sydney Jopling; Ayah Nayfeh; Brian Rush (PsyArXiv, 2023)

Psilocybin-assisted psychotherapy for the treatment of PTSD in UK armed forces veterans: A feasibility study protocol - Natasha Biscoe; Amanda Bonson; Max Slavin; Walter Busuttil; Deirdre MacManus; Andrew T. Cox; Dominic Murphy (European Journal of Trauma & Dissociation, 2023)

Extended difficulties following the use of psychedelic drugs: A mixed methods study - Jules Evans; Oliver Robinson; Eirini K. Argyri; Shayam Suseelan; Ashleigh Murphy-Beiner; Rosalind McAlpine; David Luke; Katrina Michelle; Ed Prideaux (PLoS ONE, 2023)

Pharmacological and behavioral effects of tryptamines present in psilocybin-containing mushrooms - Rakoczy RJ; Runge GN; Sen AK; Sandoval O; Nguyen Q; Roberts BR; Sciortino JH; Gibbons WJ; Friedberg LM; Andrew Jones J; McMurray MS. (bioRxiv, 2023)

Is psilocybin effective for treatment of depression? - Lucia Carbajal; Tessa E. Moore; R. H. Barry Sample; Joseph Nelson (Evidence-Based Practice, 2023)

Christian Responses to Psilocybin-Assisted Therapy and Potential Religious and Spiritual Experiences - Brian Macallan (Religions, 2023)

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use - Mathai DS; Roberts DE; Nayak SM; Sepeda ND; Lehrner A; Johnson M; Lowe MX; Jackson H; Garcia-Romeu A. (PsyArXiv, 2023)

Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences. - Rieser NM; Gubser LP; Moujaes F; Duerler P; Lewis CR; Michels L; Vollenweider FX; Preller KH (Scientific reports, 2023)

Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use - David S Mathai; Daniel E Roberts; Sandeep M Nayak; Nathan D Sepeda; Amy Lehrner; Matthew Johnson; Matthew X Lowe; Heather Jackson; Albert Garcia-Romeu (PsyArXiv, 2023)

Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders? - Ian B. Hickie; Allan H. Young; F. Markus Leweke (Research Directions Depression, 2023)

The Psychedelic,-Dipropyltryptamine Prevents Seizures in a Mouse Model of Fragile X Syndrome via a Mechanism that Appears Independent of Serotonin and Sigma1 Receptors. - Tyagi R; Saraf TS; Canal CE (ACS pharmacology & translational science, 2023)

Assessing Metro Vancouver Residents’ Knowledge and Opinions of Psilocybin - Payman Baharmand; Amardeep Kambo (BCIT Environmental Public Health Journal, 2023)

Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II - Yale University (ClinicalTrials.gov, 2023)

Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study I - Yale University (ClinicalTrials.gov, 2023)

Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential. - Kargbo RB (ACS medicinal chemistry letters, 2023)

Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study - Enriquez-Geppert S; Krc J; O'Higgins F; Lietz MP. (PsyArXiv, 2023)

Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study - Stefanie Enriquez-Geppert; Jaroslav Krc; Fiachra O'Higgins; Morten P. Lietz (PsyArXiv, 2023)

Psilocybin, Depression, and Synaptogenesis: Insights into the Field’s Past, Present, and Future - Anna Douglas; Daniel Staas; Anna Hampton; Kylie Burns; F. Suter (Georgetown Scientific Research Journal, 2023)

Synergistic, Multi-level Understanding of Psychedelics: Three Systematic Reviews and Meta-analyses of Their Pharmacology, Neuroimaging and Phenomenology - Shinozuka K; Jerotic K; Mediano P; Zhao AT; Preller KH; Carhart-Harris R; Kringelbach ML. (bioRxiv, 2023)

Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts? - Robert H. Dworkin; Michael McDermott; Sandeep M. Nayak; Eric C. Strain (Clinical Pharmacology & Therapeutics, 2023)

An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1). - Donegan CJ; Daldegan-Bueno D; Sumner R; Menkes D; Evans W; Hoeh N; Sundram F; Reynolds L; Ponton R; Cavadino A; Smith T; Roop P; et al. (Pilot and feasibility studies, 2023)

UNRAVELLING THE ROLE OF5-HT2AR ACTIVATION IN THE LONG-LASTING BEHAVIORAL EFFECTS OF PSILOCYBIN - Chloé Galipeau; Miguel Farinha-Ferreira; Jean-Charles Mariani; Samuel Diebolt; Louis Barthe; Renata Santos; Zsolt Lenkei; Ana M. Sebastião (IBRO Neuroscience Reports, 2023)

MODULATION OF SYNAPTIC FUNCTION AND NEURONAL NETWORK ACTIVITY BY SEROTONERGIC PSYCHEDELICS - Aneta Petrušková; Eva-Maria Weiss; Debarpan Guhathakurta; Enes Yağız Akdaş; Bartomeu Perelló; Renato Frischknecht; Tomáš Páleníček; Anna Fejtová (IBRO Neuroscience Reports, 2023)

PSILOCYBIN EXERTS ANTIDEPRESSANT EFFECTS IN A CHRONIC UNPREDICTABLE MILD STRESS (CUMS) ANIMAL MODEL - Ines Erkizia-Santamaría; J. Javier Meana; Igor Horrillo; Jorge E. Ortega (IBRO Neuroscience Reports, 2023)

DOES THE PHENOMENOLOGY OF THE PSILOCYBIN EXPERIENCE PREDICT LONG-TERM EFFECTS ON MOOD AND WELL-BEING IN HEALTHY VOLUNTEERS? - Tomáš Páleníček; Tereza Klučková; M. Nikolič; Čestmír Vejmola; Filip Tylš; Vojtěch Viktorin; Jiřı́ Horáček; Martin Brunovský (IBRO Neuroscience Reports, 2023)

6.3 Psilocybin Therapy for the Treatment of Young Adults With Anorexia Nervosa: State of the Research - Amanda E. Downey (Journal of the American Academy of Child & Adolescent Psychiatry, 2023)

Psilocybin kann offenbar Depressionen lindern. - Müller T. (MMW Fortschritte der Medizin, 2023)

CROSS-SPECIES EVIDENCE FOR PSILOCIN-INDUCED VISUAL HALLUCINATIONS: RATS PERCEIVE QUALITATIVELY SIMILAR CHANGES AS HUMANS - Vejmola Cestmir; Syrová Kateřina; Šíchová Klára; Koudelka Vlastimil; Hubený Jan; Kluckova Tereza; Nikolic Marek; Kelemen Eduard; Páleníček Tomáš (IBRO Neuroscience Reports, 2023)

Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis. - Gold ND; Mallard AJ; Hermann JC; Zeifman RJ; Pagni BA; Bogenschutz MP; Ross S (Journal of palliative medicine, 2023)

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. - Ley L; Holze F; Arikci D; Becker AM; Straumann I; Klaiber A; Coviello F; Dierbach S; Thomann J; Duthaler U; Luethi D; Varghese N; et al. (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2023)

Letter to the editor on "Increased low-frequency brain responses to music after psilocybin therapy for depression". - Brown O (Journal of affective disorders, 2023)

Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms. - Calder A; Mock S; Friedli N; Pasi P; Hasler G (European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2023)

Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations. - Wolfgang AS; Hoge CW (Current psychiatry reports, 2023)

The zebrafish for preclinical psilocybin research. - Syed OA; Tsang B; Gerlai R (Neuroscience and biobehavioral reviews, 2023)

Use of Psychedelics for Pain: A Scoping Review. - Goel A; Rai Y; Sivadas S; Diep C; Clarke H; Shanthanna H; Ladha KS (Anesthesiology, 2023)

Psychedelics as Therapeutics: Research Advances and Implications for Practice - Kevin M. Gray; Paul E. Croarkin (Journal of the American Academy of Child & Adolescent Psychiatry, 2023)

Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence - University of New Mexico (ClinicalTrials.gov, 2023)

Limbic System Response to Psilocybin and Ketamine Administration in Rats: A Neurochemical and Behavioral Study - Wojtas A; Bysiek A; Wawrzczak-Bargiela A; Maćkowiak M; Gołembiowska K. (Preprints.org, 2023)

Psilocybin-Assisted Therapy: A scoping review of participants’ and facilitators’ experiences in qualitative studies - Schuitmaker Nicole (Research, Society and Development, 2023)

Expectancies for Subjective and Antidepressant Effects in Psilocybin Users - Mitch Earleywine; Maha N. Mian; Joseph A. De Leo (Journal of Humanistic Psychology, 2023)

Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced Meditators - Milan Scheidegger (ClinicalTrials.gov, 2023)

Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder - University of Zurich (ClinicalTrials.gov, 2023)

Self-perception and self-recognition while looking in the mirror on psilocybin - Sam Elias; Stephanie Spivak; Alexa Alverez; Alejandro Gili Olivares; Maria Ferrol; Julian Paul Keenan (Journal of Psychedelic Studies, 2023)

Dynamic Functional Hyperconnectivity after Psilocybin Intake is Primarily Associated with Oceanic Boundlessness - Mortaheb S; Fort LD; Mason NL; Mallaroni P; Ramaekers JG; Demertzi A. (bioRxiv, 2023)

The psychedelic experience and treatment-resistant depression - Guy M. Goodwin (World Psychiatry, 2023)

Psychedelics: Threshold of a Therapeutic Revolution. - Heal DJ; Smith SL; Belouin SJ; Henningfield JE (Neuropharmacology, 2023)

Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted Conditions - Lobe Sciences Ltd. (ClinicalTrials.gov, 2023)

Can a single dose of psilocybin improve cognitive control in functional dissociative seizures? - Julien Chupin; Jorge López-Castromán; Caroline Brière; Fabrício Pereira; Coraline Hingray; Ismaël Conejero (Medical Hypotheses, 2023)

A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic amines - Chen Xue; Jing Li; Lisa Yu; Francesca Maule; Li-Mei Chang; Jonathan Gallant; David J. Press; Sheetal A. Raithatha; Jillian M. Hagel; Peter J. Facchini (Journal of Biological Chemistry, 2023)

Classic Psychedelics for the Treatment of Depressive Disorders: An Update for Psychiatrists in Training - Lawrence Canale; Dhvanit Raval; Preet Chatha; Katie Penn; Claudia Weber; Catherine Stout; Jeremy Weleff (American Journal of Psychiatry Residents Journal, 2023)

Psilocybin for anorexia nervosa: If it helps, let's learn how. - Attia E; Steinglass JE (Med (New York, N.Y.), 2023)

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. - Raison CL; Sanacora G; Woolley J; Heinzerling K; Dunlop BW; Brown RT; Kakar R; Hassman M; Trivedi RP; Robison R; Gukasyan N; Nayak SM; et al. (JAMA, 2023)

Comparison of fragrance and flavor components in non-psilocybin and psilocybin mushrooms using vacuum-assisted headspace high-capacity solid-phase microextraction and gas chromatography-mass spectrometry - Shannon L. Thomas; Colton Myers; Kevin A. Schug (Advances in Sample Preparation, 2023)

Psilocybin Use in Palliative Care #464 - Mark D. Sims; John Hendrick (Journal of Palliative Medicine, 2023)

Neuroimaging in psychedelic drug development: past, present, and future. - Wall MB; Harding R; Zafar R; Rabiner EA; Nutt DJ; Erritzoe D (Molecular psychiatry, 2023)

P05-02: Assessment of the CYP450 inhibitory activity of psilocybin, psilocin, LSD, 5-MeO-DMT and mescaline: An in vitro study - Costa A.M.; Silva-Carvalho M.; Madureira-Carvalho A.; Dinis-Oliveira R.J.; Dias-da-Silva D. (Toxicology Letters, 2023)

Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models - Ezeaka Udoka C.; Kim Hye Ji J.; Laprairie Robert B. (Current Topics in Medicinal Chemistry, 2023)

Psychedelics for Patients With Cancer: A Comprehensive Literature Review. - White CM; Weisman N; Dalo J (The Annals of pharmacotherapy, 2023)

HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer. - Lewis BR; Garland EL; Byrne K; Durns T; Hendrick J; Beck A; Thielking P (Journal of pain and symptom management, 2023)

Psilocybin intoxication did not affect daytime or sleep-related declarative memory consolidation in a small sample exploratory analysis. - Nikolič M; Viktorin V; Zach P; Tylš F; Dudysová D; Janků K; Kopřivová J; Kuchař M; Brunovský M; Horáček J; Páleníček T (European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2023)

Psilocybin: The most effective moral bio-enhancer? - Rakić V (Bioethics, 2023)

Clinical specificity profile for novel rapid acting antidepressant drugs. - Scala M; Fanelli G; De Ronchi D; Serretti A; Fabbri C (International clinical psychopharmacology, 2023)

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. - Goodwin GM; Croal M; Feifel D; Kelly JR; Marwood L; Mistry S; O'Keane V; Peck SK; Simmons H; Sisa C; Stansfield SC; Tsai J; et al. (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2023)

Bayesian analysis of real-world data as evidence for drug approval: Remembering Sir Michael Rawlins. - Szigeti B; Phillips LD; Nutt D (British journal of clinical pharmacology, 2023)

Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters. - Jahanabadi S; Amiri S; Karkeh-Abadi M; Razmi A (Fitoterapia, 2023)

Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis. - Simonsson O; Carlbring P; Carhart-Harris R; Davis AK; Nutt DJ; Griffiths RR; Erritzoe D; Goldberg SB (Psychiatry research, 2023)

The Potential of Psychedelics for the Treatment of Episodic Migraine. - Schindler EAD (Current pain and headache reports, 2023)

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. - Tagen M; Mantuani D; van Heerden L; Holstein A; Klumpers LE; Knowles R (Journal of psychopharmacology (Oxford, England), 2023)

Psilocybin history, action and reaction: A narrative clinical review. - Sharma P; Nguyen QA; Matthews SJ; Carpenter E; Mathews DB; Patten CA; Hammond CJ (Journal of psychopharmacology (Oxford, England), 2023)

Psychedelics, With a Focus on Psilocybin: Issues for the Clinician. - Garakani A; Alexander JL; Sumner CR; Pine JH; Gross LS; Raison CL; Aaronson ST; Baron DA (Journal of psychiatric practice, 2023)

Applying Key Lessons from the Hospice and Palliative Care Movement to Inform Psychedelic-Assisted Therapy. - Miller M; Rosa WE; Doerner Rinaldi A; Addicott K; Spence D; Beaussant Y (Psychedelic medicine (New Rochelle, N.Y.), 2023)

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats. - Kiilerich KF; Lorenz J; Scharff MB; Speth N; Brandt TG; Czurylo J; Xiong M; Jessen NS; Casado-Sainz A; Shalgunov V; Kjaerby C; Satała G; et al. (Molecular psychiatry, 2023)

Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin. - Bhuiya NMA; Jacobs RJ; Wang K; Sun Y; Nava B; Sampiere L; Yerubandi A; Caballero J (Cureus, 2023)

Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter? - Pagán AF; Lex C; Soares JC; Meyer TD (Psychedelic medicine (New Rochelle, N.Y.), 2023)

Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States. - Herrmann Z; Levin AW; Cole SP; Slabaugh S; Barnett B; Penn A; Jain R; Raison C; Rajanna B; Jain S (Psychedelic medicine (New Rochelle, N.Y.), 2023)

Pharmacology and Therapeutic Effects of Psilocybin - Xuehan Du (Highlights in Science Engineering and Technology, 2023)

Intravenous psilocybin administration attenuates mechanical hypersensitivity in a rat model of chronic pain - Kolbman N; Liu T; Guzzo P; Gilligan JP; Mashour GA; Vanini G; Pal D. (bioRxiv, 2023)

Psilocybin desynchronizes brain networks. - Siegel JS; Subramanian S; Perry D; Kay B; Gordon E; Laumann T; Reneau R; Gratton C; Horan C; Metcalf N; Chacko R; Schweiger J; et al. (medRxiv: the preprint server for health sciences, 2023)

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences. - Zeifman RJ; Kettner H; Pagni BA; Mallard A; Roberts DE; Erritzoe D; Ross S; Carhart-Harris RL (Scientific reports, 2023)

Exploring the relationship between mental health, drug use, personality, and attitudes towards psilocybin-assisted therapy - Benjamin M. Ross; James T. Neill (Journal of Psychedelic Studies, 2023)

“Diversity makes the richness of humanity”: the emergence of mental imagery after self-reported psilocybin mushrooms intake in an autistic woman with “blind imagination” (aphantasia): a 1-year retrospective case report - Rebecchi K. (PsyArXiv, 2023)

“Diversity makes the richness of humanity”: the emergence of mental imagery after self-reported psilocybin mushrooms intake in an autistic woman with “blind imagination” (aphantasia): a 1-year retrospective case report - Kevin Rebecchi (PsyArXiv, 2023)

use of psilocybin in the treatment of psychiatric disorders - review - Justyna Woźniak; Rafał BOGACZ; Magdalena Gaik; Ewa URAM; Inga MAGDA; Karol Womperski; Magdalena OSUCH (Journal of Education Health and Sport, 2023)

Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy - Nick Zagorski (Psychiatric News, 2023)

A Phase 1, Two-Part Study in Healthy Volunteers to Evaluate The Effect of Psilocybin on Cardiac Repolarization and The Effect of Food on Psilocybin Pharmacokinetics - Usona Institute (ClinicalTrials.gov, 2023)

Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells. - Robinson GI; Li D; Wang B; Zahoruiko Y; Gerasymchuk M; Hudson D; Kovalchuk O; Kovalchuk I (Current issues in molecular biology, 2023)

Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy. - Thase ME (The Journal of clinical psychiatry, 2023)

Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice. - Jones NT; Zahid Z; Grady SM; Sultan ZW; Zheng Z; Razidlo J; Banks MI; Wenthur CJ (ACS pharmacology & translational science, 2023)

Emerging Perspectives in Addiction Psychiatry. - Jordan A (The Journal of clinical psychiatry, 2023)

Substance use, harm reduction attitudes and behaviors among attendees of nature rave parties in Israel. - Bonny-Noach H; Shapira B; Baumol P; Tadmor N; Rosca P; Shoshan S; Harel-Fisch Y; Caduri A (Harm reduction journal, 2023)

Psilocybin's Emerging Role in Combating Depressive Disorder - Anna Jaremek; Joanna Kępa; Norbert Kandefer; Michał Wyszkowski; Aleksandra Grabarczyk; Anna Pawlak; Sylwia Grad; Małgorzata Gregorek; Paweł Gregorek (Journal of Education Health and Sport, 2023)

Psilocybin-assisted psychotherapy for cancer-related anxiety and depression. - Yaniv D; Ramondetta LM; Cohen L; Amit M (International journal of gynecological cancer: official journal of the International Gynecological Cancer Society, 2023)

A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression. - Pilozzi A; Foster S; Mischoulon D; Fava M; Huang X (International journal of molecular sciences, 2023)

[Not Available]. - Ibrahim IB; Videbech P; Straszek SPV (Ugeskrift for laeger, 2023)

Psilocybin und Funktionalität bei Depression - Moritz Spangemacher (InFo Neurologie + Psychiatrie, 2023)

Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. - Dodd S; Norman TR; Eyre HA; Stahl SM; Phillips A; Carvalho AF; Berk M (CNS spectrums, 2023)

Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis. - Crowe M; Manuel J; Carlyle D; Lacey C (International journal of mental health nursing, 2023)

Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. - Zia FZ; Baumann MH; Belouin SJ; Dworkin RH; Ghauri MH; Hendricks PS; Henningfield JE; Lanier RK; Ross S; Berger A (Neuropharmacology, 2023)

How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. - Zeifman RJ; Wagner AC; Monson CM; Carhart-Harris RL (Journal of affective disorders, 2023)

Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022. - Jing X; Hoeh NR; Menkes DB (Palliative & supportive care, 2023)

"Biosynthesis of psilocybin and its nonnatural derivatives by a promiscuous psilocybin synthesis pathway in Escherichia coli". - Flower JE; Gibbons WJ; Adams AM; Wang X; Broude CN; Jones JA (Biotechnology and bioengineering, 2023)

Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants. - Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; et al. (Pharmacological research, 2023)